Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of TT-01488 combined with an anti-CD20 monoclonal antibody-containing regimen in mantle cell lymphoma
CTR20263426Phase 2Active
- Sponsor
- TransThera Biosciences
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TT-01488 in mantle cell lymphoma (MCL), sponsored by TransThera Biosciences. Started Sep 2026; status: active.
02
Drugs
TT-01488
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on CTR20263426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263426.